Literature DB >> 36262401

Novel Substituted Cyclopropyl Compounds as CFTR Modulators for Treating Cystic Fibrosis.

Ram W Sabnis1.   

Abstract

Provided herein are novel substituted cyclopropyl compounds as CFTR modulators, pharmaceutical compositions, use of such compounds in treating cystic fibrosis, and processes for preparing such compounds. Published 2022 by American Chemical Society.

Entities:  

Year:  2022        PMID： 36262401      PMCID： PMC9575177          DOI： 10.1021/acsmedchemlett.2c00406

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.632


  6 in total

Review 1.  Small-molecule drugs for cystic fibrosis: Where are we now?

Authors:  Onofrio Laselva; Lorenzo Guerra; Stefano Castellani; Maria Favia; Sante Di Gioia; Massimo Conese
Journal:  Pulm Pharmacol Ther       Date:  2021-11-15       Impact factor: 3.410

Review 2.  Cystic fibrosis-related liver disease: Clinical presentations, diagnostic and monitoring approaches in the era of CFTR modulator therapies.

Authors:  Jérémy Dana; Dominique Debray; Aurélie Beaufrère; Sophie Hillaire; Monique Fabre; Caroline Reinhold; Thomas F Baumert; Laureline Berteloot; Valérie Vilgrain
Journal:  J Hepatol       Date:  2021-10-20       Impact factor: 25.083

Review 3.  Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening, and Treatment Challenges: Adult Cystic Fibrosis Series.

Authors:  Patrick Maisonneuve; Albert B Lowenfels
Journal:  Chest       Date:  2021-09-15       Impact factor: 9.410

Review 4.  Cystic fibrosis year in review 2020: Section 2 pulmonary disease, infections, and inflammation.

Authors:  Nicholas J Antos; Adrienne P Savant
Journal:  Pediatr Pulmonol       Date:  2021-05-25

Review 5.  Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies.

Authors:  Jessica E Caterini; Felix Ratjen; Alan R Barker; Craig A Williams; Kate Rendall; Jane E Schneiderman; Greg D Wells
Journal:  J Cyst Fibros       Date:  2021-12-24       Impact factor: 5.482

Review 6.  Cardiovascular complications in cystic fibrosis: A review of the literature.

Authors:  T Spencer Poore; Jennifer L Taylor-Cousar; Edith T Zemanick
Journal:  J Cyst Fibros       Date:  2021-06-14       Impact factor: 5.482
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.